Medicines agency publishes Brexit guidelines

The European Medicines Agency has issued a fact sheet for pharmaceutical companies concerned about accessing UK and European markets post-Brexit.

The EMA’s list was drafted jointly with the European Commission. It states that companies based in the UK will need to transfer their market authorisation to an EU address to continue selling their products in Europe.

The notice was sent to all marketing authorisation holders for human and veterinary medicines. It said that "unless the withdrawal agreement establishes another date or the period is extended by the European Council in accordance with Article 50, all EU primary and secondary law ceases to apply to the UK from 30 March 2019. The UK will then become a ‘third country’.”